Jeffrey G. Supko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey G. Supko has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Andre Goy
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey
12 shared publications - Ian W. Flinn
Tennessee Oncology, Nashville, TN
12 shared publications - Jeremy S. Abramson
Massachusetts General Hospital, Boston, MA
12 shared publications - Kristie A. Blum
The Ohio State University, Columbus, OH
12 shared publications Sergey Efuni
12 shared publications- Suresh Bobba
Keros Therapeutics, Lexington, MA
12 shared publications
Latest Publications
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Figure 1. Differential expression analysis based on per-pixel adavosertib mass spectrometry imaging drug distribution (p-value = 0.115, t-test). Boxplot show the median, 25% and 75% quantiles.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Figure 1. Differential expression analysis based on per-pixel adavosertib mass spectrometry imaging drug distribution (p-value = 0.115, t-test). Boxplot show the median, 25% and 75% quantiles.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Table 1. Representativeness of Study Participants.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Table 2. Estimated Pharmacokinetic values for AZD 1775.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Table 2. Estimated Pharmacokinetic values for AZD 1775.
- 17 January 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (6) , 983-992
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Purpose: Adavosertib is an oral small-molecule inhibitor of Wee1. The Adult Brain Tumor Consortium conducted a phase I study evaluating adavosertib in combination with radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM), as well as a surgical window-of-opportunity study in recurrent GBM. Patients and Methods: The MTD of adavosertib was determined in adult patients with newly diagnosed GBM using a standard 3+3 design in two separate cohorts: with concurrent RT/TMZ or with adjuvant TMZ. A combination cohort with both concurrent and adjuvant adavosertib at MTD followed. We also performed intratumoral drug distribution studies in patients with recurrent GBM undergoing surgery. Results: As separate cohorts, the MTD for concurrent adavosertib with RT/TMZ was 200 mg daily Monday through Friday × 6 weeks during RT, and the MTD for adjuvant adavosertib with TMZ was 425 mg daily for 5 days of each 28-day cycle. However, six of 12 patients experienced dose-limiting toxicities (DLT) in the combination cohort. The mean ratios of the intratumoral to plasma concentration of adavosertib were 4.18 ± 3.36 for contrast-enhancing tissue and 0.74 ± 0.63 in nonenhancing tissue. Conclusions: Adavosertib at 200 mg daily Monday through Friday × 6 weeks with RT/TMZ and at 425 mg daily on a 5-day/28-day cycle with TMZ had an unacceptable DLT rate. Additional dose levels in combination cohorts resulted in DLT, and we deemed concurrent adavosertib too toxic for further examination. Adavosertib 425 mg daily on a 5-day/28-day cycle with adjuvant TMZ is the recommended phase II dosage. Tissue pharmacokinetics in tissue homogenates and by microdialysis provided complementary information about drug penetration.
- 17 January 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (6) , 983-992
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Purpose: Adavosertib is an oral small-molecule inhibitor of Wee1. The Adult Brain Tumor Consortium conducted a phase I study evaluating adavosertib in combination with radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM), as well as a surgical window-of-opportunity study in recurrent GBM. Patients and Methods: The MTD of adavosertib was determined in adult patients with newly diagnosed GBM using a standard 3+3 design in two separate cohorts: with concurrent RT/TMZ or with adjuvant TMZ. A combination cohort with both concurrent and adjuvant adavosertib at MTD followed. We also performed intratumoral drug distribution studies in patients with recurrent GBM undergoing surgery. Results: As separate cohorts, the MTD for concurrent adavosertib with RT/TMZ was 200 mg daily Monday through Friday × 6 weeks during RT, and the MTD for adjuvant adavosertib with TMZ was 425 mg daily for 5 days of each 28-day cycle. However, six of 12 patients experienced dose-limiting toxicities (DLT) in the combination cohort. The mean ratios of the intratumoral to plasma concentration of adavosertib were 4.18 ± 3.36 for contrast-enhancing tissue and 0.74 ± 0.63 in nonenhancing tissue. Conclusions: Adavosertib at 200 mg daily Monday through Friday × 6 weeks with RT/TMZ and at 425 mg daily on a 5-day/28-day cycle with TMZ had an unacceptable DLT rate. Additional dose levels in combination cohorts resulted in DLT, and we deemed concurrent adavosertib too toxic for further examination. Adavosertib 425 mg daily on a 5-day/28-day cycle with adjuvant TMZ is the recommended phase II dosage. Tissue pharmacokinetics in tissue homogenates and by microdialysis provided complementary information about drug penetration.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Supplemental tables with the number of patients treated with number of cycles and the incidence of DLTs.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Supplemental tables with the number of patients treated with number of cycles and the incidence of DLTs.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Representative image of complete response after treatment with pelabresib.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Representative image of complete response after treatment with pelabresib.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
PK/PD Analysis of the Relationship Between Maximum Relative Change in Gene Expression and Pelabresib Exposure Metrics.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
PK/PD Analysis of the Relationship Between Maximum Relative Change in Gene Expression and Pelabresib Exposure Metrics.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
CONSORT diagram of patient disposition throughout study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
CONSORT diagram of patient disposition throughout study